| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $13,382,148 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS120930 | Molecular basis for adenosine A3 receptor agonists in the treatment of migraine | 000 | 5 | NIH | 12/18/2025 | $425,628 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R37MH080046 | Internal Dynamics of the Postsynaptic Density | 000 | 19 | NIH | 12/23/2025 | $679,801 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 7 | NIH | 12/18/2025 | $617,961 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UM1AI148689 | Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | 000 | 7 | NIH | 12/18/2025 | $309,697 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F31DA062453 | The Impact of Perinatal Fentanyl on Dopamine Neuron Circuitry and Behavior | 000 | 2 | NIH | 12/19/2025 | $46,528 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG081693 | Deep-Learning Enhanced ASL MRI For Early AD Assessment | 000 | 3 | NIH | 12/11/2025 | $682,656 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00DK131018 | Unravelling the Role of Epigenetics and Cytokines in Type 2 Diabetes among African-ancestry Populations | 000 | 4 | NIH | 12/18/2025 | $242,695 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R00CA273171 | Investigating the role of neddylation in the repair of topoisomerase I inhibitor-induced replication damage in colorectal cancer | 000 | 3 | NIH | 12/5/2025 | $224,100 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI168192 | Mechanisms coordinating the local and systemic resistance to pathogens | 000 | 4 | NIH | 11/26/2025 | $565,170 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI172487 | Broadly neutralizing antibody combinations with single virions in HIV+ plasma | 000 | 4 | NIH | 12/19/2025 | $386,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI176333 | New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections | 000 | 4 | NIH | 12/18/2025 | $597,100 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AR083363 | Lipid metabolism in the growth plate | 000 | 3 | NIH | 11/25/2025 | $482,145 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA273216 | Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer | 000 | 5 | NIH | 12/24/2025 | $581,504 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA279108 | The pro-metastatic role of androgen receptor in estrogen receptor mutated breast cancer | 000 | 3 | NIH | 12/22/2025 | $558,043 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA285468 | First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers | 000 | 3 | NIH | 12/22/2025 | $577,013 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA290796 | An engineered prodrug for inhibition of cancer growth and metastasis | 000 | 2 | NIH | 12/23/2025 | $389,640 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA298839 | Tumor-associated pDC (TApDC) in liver cancer with HIV infection | 000 | 2 | NIH | 12/11/2025 | $570,655 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK074797 | Inter-organ signaling in heme metabolism and organismal homeostasis. | 000 | 15 | NIH | 12/30/2025 | $397,410 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK133421 | Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | 000 | 4 | NIH | 12/30/2025 | $538,952 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK130238 | Pharmacogenetics of the Response to a GLP1R Agonist | 000 | 5 | NIH | 12/4/2025 | $672,063 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS117102 | Stem Cell Surface Modification to Promote Nerve Regeneration | 000 | 5 | NIH | 12/18/2025 | $386,953 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM156369 | Conformational Dynamics and Regulatory Mechanisms in the KCNH Family of Ion Channels | 000 | 2 | NIH | 12/24/2025 | $384,863 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS129502 | Role of reactive astrocytes in prion diseases | 000 | 4 | NIH | 12/9/2025 | $560,291 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21HL172155 | Integration of Pharmacogenomics and Metabolomics in the Study of Antiplatelet Efficacy | 000 | 2 | NIH | 12/12/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R24DA061178 | ARTEMIS: Advancing Addiction Research and Treatment through Engagement with Rural Marylanders Impacted by PolySubstance Use | 000 | 2 | NIH | 12/18/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R35GM140822 | Extracellular miRNAs, innate immunity, and critical illness | 000 | 5 | NIH | 12/1/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | T32AG000262 | Research Training in the Epidemiology of Aging | 000 | 28 | NIH | 11/21/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U01DC013817 | Cell Type Specific Transcriptional Cascades in Inner Ear Development | 000 | 10 | NIH | 11/17/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U24HG012557 | The Human Disease Ontology: An integrated, mechanistic knowledge resource for biomedical research. | 000 | 4 | NIH | 12/15/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U54CK000615 | RFA-CK20-004: Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events | 01 | 5 | CDC | 11/17/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UH3HL143192 | Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE | 000 | 8 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | F30HD107942 | The impact of proliferating mast cells in the developing brain | 000 | 4 | NIH | 12/17/2025 | -$24,685 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U4C49932 | Pediatric Mental Health Care Access Program | 08 | 2 | HRSA | 12/4/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | NU58DP007088 | National Initiative to Advance Health Equity in K-12 Education by Preventing Chronic Disease and Promoting Healthy Behaviors: Priority 2-Emotional Well-Being | 02 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AG070072 | Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model | 000 | 5 | NIH | 10/7/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI147331 | Impact of Non - B HIV - 1 Subtype on second line Protease Inhibitor Regimens in Africa (INSPIRE) | 000 | 5 | NIH | 10/14/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI161839 | Broad spectrum Shigella subunit vaccine based on conserved proteins | 000 | 5 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI181383 | Impact of early childhood malaria prevention on malaria risk at school entry (ERASE) | 001 | 2 | NIH | 12/16/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI181383 | Impact of early childhood malaria prevention on malaria risk at school entry (ERASE) | 000 | 2 | NIH | 12/16/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AR083363 | Lipid metabolism in the growth plate | 001 | 2 | NIH | 12/24/2025 | $37,500 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA063090 | Joint decomposition of SCORCH mulit-omic data to explore the impact of SUD and HIV on reward circuitry and neuroinflammation | 000 | 1 | NIH | 12/5/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01GM140983 | Trauma and Shock-Induced Microvascular Dysregulation and Coagulopathy | 000 | 4 | NIH | 11/21/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD093070 | VEGF Gene Delivery In The Primate To Prevent Defective Spiral Artery Remodeling And Maternal Vascular Dysfunction | 000 | 7 | NIH | 12/19/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD119968 | Cross-disciplinary approach to understanding the long-term impact of HIV exposure in children | 000 | 1 | NIH | 12/24/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HD119968 | Cross-disciplinary approach to understanding the long-term impact of HIV exposure in children | 000 | 1 | NIH | 12/24/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL162120 | Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis | 000 | 4 | NIH | 11/14/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI177237 | Molecular mechanisms of anthrax toxin unfolding and translocation | 000 | 1 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R36AG080272 | Motor learning of protective responses to balance perturbations in persons with Parkinson's Disease | 000 | 2 | NIH | 12/8/2025 | -$17,428 |
| | 2026 | 2024 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U18FD007054 | Center for Research on Complex Generics | 000 | 5 | FDA | 12/29/2025 | $1,500,000 |
|
